Literature DB >> 29296781

Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT.

Aliénor Xhaard1, Renato Cunha2, Marc Busson1, Marie Robin1, Nathalie Dhedin3, Tereza Coman1, Aurélie Cabannes-Hamy3, Flore Sicre de Fontbrune1, David Michonneau1, Gérard Socié1,4, Rodrigo T Calado2, Régis Peffault de Latour1.   

Abstract

Various pretransplant patient and disease characteristics are associated with treatment-related mortality (TRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, TRM cannot yet be satisfactorily predicted. We prospectively investigated the aggregate impact of pretransplant clinical variables (period, donor/recipient age, gender, cytomegalovirus status, disease risk, stem cell source, and HLA matching), comorbidity index scores (Hematopoietic Cell Transplantation Comorbidity Index), and biological markers (telomere length, ferritin, and C-reactive protein) on TRM in single-center patients receiving a first allo-HSCT. From 2006 to 2012, all variables were available for 178 patients. In multivariate analysis, only mismatched unrelated donor (hazard ratio [HR], 2.79; 95% confidence interval [CI], 1.19-6.58; P = .019) and shorter age-adjusted recipient telomere length (HR, 2.17; 95% CI, 1.03-4.57; P = .041) were independently associated with TRM. Pre-allo-HSCT age-adjusted telomere length thus appears to be a useful new predictor of TRM in the setting of HSCT.

Entities:  

Year:  2017        PMID: 29296781      PMCID: PMC5727857          DOI: 10.1182/bloodadvances.2017008094

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  12 in total

1.  Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.

Authors:  Régis Peffault de Latour; Rodrigo T Calado; Marc Busson; Jeffrey Abrams; Nadir Adoui; Marie Robin; Jérôme Larghero; Nathalie Dhedin; Alienor Xhaard; Emmanuel Clave; Dominique Charron; Antoine Toubert; Pascale Loiseau; Gérard Socié; Neal S Young
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

2.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Andrew S Artz; Brent Logan; Xiaochun Zhu; Gorgun Akpek; Rodrigo Martino Bufarull; Vikas Gupta; Hillard M Lazarus; Mark Litzow; Alison Loren; Navneet S Majhail; Richard T Maziarz; Philip McCarthy; Uday Popat; Wael Saber; Stephen Spellman; Olle Ringden; Amittha Wickrema; Marcelo C Pasquini; Kenneth R Cooke
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

5.  C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.

Authors:  Mats Remberger; Jonas Mattsson
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

6.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Robert J Soiffer; Joseph H Antin
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

7.  Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Soichiro Sakamoto; Hiroshi Kawabata; Junya Kanda; Tatsuki Uchiyama; Chisaki Mizumoto; Tadakazu Kondo; Kouhei Yamashita; Tatsuo Ichinohe; Takayuki Ishikawa; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2012-12-07       Impact factor: 2.490

8.  Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation.

Authors:  Şahika Zeynep Akı; Elif Suyanı; Yelda Bildacı; Merih Kızıl Çakar; Nuran Ahu Baysal; Gülsan Türköz Sucak
Journal:  Clin Transplant       Date:  2012 Sep-Oct       Impact factor: 2.863

9.  Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT.

Authors:  M Sato; H Nakasone; K Oshima; Y Ishihara; H Wada; K Sakamoto; K Kawamura; M Ashizawa; T Machishima; K Terasako; S Kimura; M Kikuchi; S Okuda; A Tanihara; R Yamazaki; Y Tanaka; J Kanda; S Kako; J Nishida; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-10-08       Impact factor: 5.483

10.  Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

Authors:  Wataru Yamamoto; Eriko Fujii; Kenji Matsumoto; Eri Yamamoto; Jun Aoki; Masatsugu Tanaka; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2016-01-20       Impact factor: 2.490

View more
  2 in total

1.  Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia.

Authors:  Youjin Wang; Lisa J McReynolds; Casey Dagnall; Hormuzd A Katki; Stephen R Spellman; Tao Wang; Belynda Hicks; Neal D Freedman; Kristine Jones; Stephanie J Lee; Sharon A Savage; Shahinaz M Gadalla
Journal:  Br J Haematol       Date:  2019-08-19       Impact factor: 8.615

Review 2.  Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence.

Authors:  Adam Kuba; Ludek Raida
Journal:  Mediators Inflamm       Date:  2018-03-26       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.